Norinchukin Bank The Acquires 2,920 Shares of Danaher Corporation (DHR)
Norinchukin Bank The boosted its holdings in shares of Danaher Corporation (NYSE:DHR) by 2.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 108,813 shares of the conglomerate’s stock after buying an additional 2,920 shares during the quarter. Norinchukin Bank The’s holdings in Danaher Corporation were worth $9,183,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of the business. Peddock Capital Advisors LLC grew its stake in shares of Danaher Corporation by 17.4% during the 1st quarter. Peddock Capital Advisors LLC now owns 1,224 shares of the conglomerate’s stock worth $105,000 after purchasing an additional 181 shares during the period. Proficio Capital Partners LLC grew its stake in shares of Danaher Corporation by 92.3% during the 1st quarter. Proficio Capital Partners LLC now owns 1,246 shares of the conglomerate’s stock worth $105,000 after purchasing an additional 598 shares during the period. ClariVest Asset Management LLC acquired a new stake in shares of Danaher Corporation during the 1st quarter worth approximately $157,000. Motco grew its stake in shares of Danaher Corporation by 8.8% during the 2nd quarter. Motco now owns 2,011 shares of the conglomerate’s stock worth $170,000 after purchasing an additional 163 shares during the period. Finally, Cornerstone Advisors Inc. grew its stake in shares of Danaher Corporation by 62.0% during the 2nd quarter. Cornerstone Advisors Inc. now owns 2,111 shares of the conglomerate’s stock worth $178,000 after purchasing an additional 808 shares during the period. 75.66% of the stock is owned by institutional investors.
Danaher Corporation (NYSE DHR) opened at 86.13 on Tuesday. The stock has a market cap of $59.83 billion, a price-to-earnings ratio of 27.49 and a beta of 1.03. Danaher Corporation has a 12-month low of $75.71 and a 12-month high of $88.62. The stock’s 50 day moving average price is $85.95 and its 200 day moving average price is $84.19.
Danaher Corporation (NYSE:DHR) last posted its quarterly earnings data on Thursday, July 20th. The conglomerate reported $0.99 EPS for the quarter, beating analysts’ consensus estimates of $0.97 by $0.02. The business had revenue of $4.51 billion for the quarter, compared to analyst estimates of $4.50 billion. Danaher Corporation had a return on equity of 11.15% and a net margin of 12.63%. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.90 earnings per share. Analysts forecast that Danaher Corporation will post $3.95 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 29th will be paid a dividend of $0.14 per share. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date is Thursday, September 28th. Danaher Corporation’s payout ratio is currently 17.83%.
In other Danaher Corporation news, insider Thomas Patrick Joyce, Jr. sold 9,772 shares of the firm’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $81.78, for a total value of $799,154.16. Following the sale, the insider now directly owns 155,520 shares of the company’s stock, valued at approximately $12,718,425.60. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider William King sold 43,688 shares of the firm’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $82.86, for a total value of $3,619,987.68. Following the completion of the sale, the insider now directly owns 45,748 shares in the company, valued at $3,790,679.28. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 71,496 shares of company stock worth $5,916,223. Corporate insiders own 12.20% of the company’s stock.
DHR has been the topic of a number of analyst reports. Zacks Investment Research cut shares of Danaher Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, July 27th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $83.00 price objective on shares of Danaher Corporation in a research note on Tuesday, September 26th. BidaskClub raised shares of Danaher Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $95.00 price objective on shares of Danaher Corporation in a research note on Friday, September 8th. Finally, Citigroup Inc. set a $96.00 price objective on shares of Danaher Corporation and gave the stock a “buy” rating in a research note on Friday, July 21st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $92.62.
COPYRIGHT VIOLATION WARNING: “Norinchukin Bank The Acquires 2,920 Shares of Danaher Corporation (DHR)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/10/17/norinchukin-bank-the-acquires-2920-shares-of-danaher-corporation-dhr.html.
Danaher Corporation Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Stock Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related stocks with our FREE daily email newsletter.